PDF herunterladen
CC BY-NC-ND 4.0 · J Lab Physicians 2017; 9(03): 210-213
DOI: 10.4103/0974-2727.208261
Case Report

Cotrimoxazole, a wonder drug in the era of multiresistance: Case report and review of literature

Priyam Batra
Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
,
Vishant Deo
Department of Surgery, All India Institute of Medical Sciences, New Delhi, India
,
Purva Mathur
Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India
,
Amit Kumar Gupta
Department of Lab Medicine, All India Institute of Medical Sciences, New Delhi, India
› Institutsangaben Financial support and sponsorship Nil.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

Antimicrobial resistance is one of the greatest threats to human health worldwide. The rate of development of newer antibiotics is much slower than the rate of development of antibiotic resistance. A survey reported that it takes 15 years and US$800 million (including preclinical and clinical costs) to bring a single drug to the market, whereas the reuse of the older drugs for antimicrobial use takes $17 million, thereby circumventing 40% of the overall cost. The first case is a patient with nosocomial pyrexia of unknown origin who was given treatment with tigecycline and cefepime/tazobactam but failed to respond to the same. However, the patient responded to the treatment with cotrimoxazole. The second case is a patient with meningitis caused by an atypical zoonotic pathogen, Staphylococcus chromogenes. This is the first report of human infection with S. chromogenes, this being a common cause of bovine mastitis. The isolate was obtained from a patient of neurotrauma who developed meningitis after decompressive craniotomy. The strain was obtained from cerebrospinal fluid, blood, and shunt chamber pus. Cotrimoxazole was given for the treatment, and the patient improved after the treatment. Although the newer antibiotics have replaced sulfonamides in the treatment of many infections, they are still of great value and are the agents of choice in many infections. Sulfonamides have wide antimicrobial activity against both Gram-positive and Gram-negative bacteria, but their usefulness has diminished with the emergence of resistant strains. This paper reports cases of two different kinds of infections from a level 1 trauma center, who failed to respond to the newer antibiotics but showed a response to administration of cotrimoxazole.

Key words

Cotrimoxazole - multidrug-resistant pathogens - nosocomial pyrexia of unknown origin - older antibiotic - Staphylococcus chromogenes


Publikationsverlauf

Eingereicht: 29. Juni 2016

Angenommen: 07. August 2016

Artikel online veröffentlicht:
19. Februar 2020

© 2017.

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Walker B, Barrett S, Polasky S, Galaz V, Folke C, Engström G, et al. Environment. Looming global-scale failures and missing institutions. Science 2009;325:1345-6.
  • 2 Chong CR, Sullivan DJ Jr. New uses for old drugs. Nature 2007;448:645-6.
  • 3 Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71.
  • 4 Geresu B, Misganaw D, Beyene Y. Retrospective evaluation of cotrimoxazole use as preventive therapy in people living with HIV/AIDS in Boru Meda Hospital. BMC Pharmacol Toxicol 2014;15:4.
  • 5 Patil HV, Patil VC, Rajmane V, Raje V. Successful treatment of cerebral toxoplasmosis with cotrimoxazole. Indian J Sex Transm Dis 2011;32:44-6.
  • 6 Petri WA Jr. Goodman and Gilmans the Pharmacological Basis of Therapeutics. 12th ed. San Diego, California: McGraw Hill; 2011. p. 1625-46.
  • 7 Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: Recommendations for a public health approach. Geneva: World Health Organization; 2006. Available from: http://www.who.int/hiv/pub/plhiv/ctx/en. [Last accessed on 2016 Aug 22].
  • 8 Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al. Harrison's Manual of Medicine. 17th ed. San Diego, California: McGraw Hill; 2012. p. 199-201.
  • 9 Souza FN, Piepers S, Della Libera AM, Heinemann MB, Cerqueira MM, De Vliegher S. Interaction between bovine-associated coagulase-negative Staphylococci species and strains and bovine mammary epithelial cells reflects differences in ecology and epidemiological behavior. J Dairy Sci 2016;99:2867-74.
  • 10 Taponen S, Nykäsenoja S, Pohjanvirta T, Pitkälä A, Pyörälä S. Species distribution and in vitro antimicrobial susceptibility of coagulase-negative Staphylococci isolated from bovine mastitic milk. Acta Vet Scand 2016;58:12.
  • 11 Schroeder JW. Mastitis Control Programs: Bovine Mastitis and Milking Management. NDSU Extension Service. North Dakota State University; 1997. p. 1-16. Available from: https://www.ag.ndsu.edu/pubs/ansci/dairy/as1129.pdf. [Last accessed on 2016 Jul 13].
  • 12 Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Rep 2011;3:14.
  • 13 Wu H, Wang JT, Shiau YR, Wang HY, Lauderdale TL, Chang SC; TSAR Hospitals. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 2012;45:120-6.
  • 14 Sharif A, Sharif MR, Alizargar J. Susceptibility of Gra negative bacteria to cotrimoxazole in specimens sent to the laboratory of Shahid Beheshti Hospital. Middle East J Sci Res 2014;21:440-4.
  • 15 Jain DK, Arya RK, Ranjan KP, Ranjan N. Emergence of sensitivity of cotrimoxazole in urinary tract infections. World J Pharm Res 2014;3:2172-5.